


# Nanoparticles that deliver oligonucleotide drugs into cells described

January 27 2015

---



Credit: Mary Ann Liebert, Inc., publishers

Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. A new delivery approach based on cell-penetrating

peptide nanoparticles can efficiently transport charge-neutral oligonucleotide analogs into cells, as reported in *Nucleic Acid Therapeutics*.

In the article, "[Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides](#)," Peter Järver and coauthors, Cambridge Biomedical Campus (U.K.), Karolinska University Hospital (Huddinge, Sweden), Stockholm University (Sweden), Alexandria University (Egypt), and University of Oxford (U.K.), note that while delivery systems exist to facilitate cell entry of negatively charged oligonucleotide drugs, these approaches are not effective for charge-neutral [oligonucleotide](#) analogs. The authors describe lipid-functionalized peptides that form a complex with charge-neutral morpholino oligonucleotides, enabling them to cross into cells and retain their biological activity.

"The exploitation of phosphorodiamidate morpholinos represents an exciting approach to treating a number of therapeutic targets," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. "This paper suggests an intriguing but practical approach to solving the lack of a convenient non-covalent delivery system."

**More information:** The article is available free on the [Nucleic Acid Therapeutics](#) website.

Provided by Mary Ann Liebert, Inc

Citation: Nanoparticles that deliver oligonucleotide drugs into cells described (2015, January 27) retrieved 27 April 2024 from

<https://phys.org/news/2015-01-nanoparticles-oligonucleotide-drugs-cells.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.